PharmaPoint: Melanoma-Global Drug Forecast and Market Analysis to 2023


Naperville, IL -- (SBWIRE) -- 04/23/2015 -- Reportstack, provider of premium market research reports announces the addition of PharmaPoint: Melanoma-Global Drug Forecast and Market Analysis to 2023 market report to its offering.

Melanoma is the deadliest and most aggressive form of skin cancer. The major treatments for melanoma are categorized into immunotherapies and BRAF mutation-targeted therapies. The publisher estimates the 2013 sales for melanoma at approximately $1.34 billion across the 8MM covered in this report. The market will increase by four-fold over the forecast period, reaching $5.64 billion in 2023 at a CAGR of 15.5%. This growth will be driven by an increase in melanoma incident cases as well as the approval and uptake of premium-priced products, such as PD-1-targeting mAbs and BRAF/MEK inhibitor combinations. The publisher expects, by the end of the forecast period, the checkpoint immunotherapy drug class to dominate the melanoma market (including both BRAF wild-type and mutation-positive patient segments) with an overall 67% share of the melanoma market.

The melanoma pipeline is strong; however, The publisher expects none of these drugs to have a major impact on the overall melanoma market, as the market is crowded with effective immunotherapies and BRAF mutation-targeted agents. The challenge for new entrants into the melanoma market is to find patient populations that are currently underserved. One of the opportunities for the companies is to work cooperatively to develop novel combinations of immuno/targeted-therapies.


Overview of melanoma, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

Annualized melanoma therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in six patient segments (including adjuvant, BRAF mutated and BRAF wild-type), forecast from 2013 to 2023.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the melanoma therapeutics market

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for different lines of therapy. The most promising candidate in Phase III development is profiled.

Analysis of the current and future market competition in the global melanoma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Market Model Features

An interactive excel forecast model based on primary research interviews and surveys with KOLs and high-prescribing physicians is included in this report*. This patient based model provides diagnosis rates, patient segmentation, treatment rates, annual costs of therapy , and indication-specific drug sales for the 10 year forecast period. The forecast model is robust, fully transparent, and easy to navigate. Moreover, our models support data presented in the reports and the complete methodology is outlined in the report and the model.

*Model only available with site and global license purchases.

Key Findings

One of the main drivers of the enormous expansion of the gout market will be the launch of premium-priced metastatic therapies, such as anti-PD-1 immunotherapy and BRAF/MEK inhibitor combinations. These drugs will extend treatment duration and replace cheaper, generic, chemotherapy regimens.

Another strong driver will be the label extension of current therapies into the new settings; for example, PD-1s will garner label extension for the first-line treatment in 2015–16, and the metastatic brands are expected to be approved in the adjuvant setting in the second half of the forecast period.

Companies are focusing on the development of combination immunotherapies, trying to improve the response rate and response duration of drugs.

One of the largest unmet needs is a need for efficacious treatment options for BRAF wild-type patients. Approximately half of melanoma patients do not have BRAF mutations, and are therefore non-eligible for BRAF/MEK inhibitor treatments. Other unmet needs include therapies for PD-1 immunotherapy non-responders, adjuvant treatment for patients with resected melanoma, effective treatment for brain metastasis, and predictive markers for therapeutic response to immunotherapies.

List of Companies


Array BioPharma


Bristol-Myers Squibb


Eli Lilly





Merck & Co.

Merck KGaA



NewLink Genetics










Complete report is available @

Roger Campbell
United States
Ph: 888-789-6604